OVERVIEW OF MODERN STUDIES OF COMORBIDITY IN PSORIASIS


Cite item

Full Text

Abstract

Psoriasis is a multifactorial inflammatory skin disease associated with various medical conditions. The article presents an overview associations between psoriasis and ulcerative colitis, diabetes, chronic neuropathy, depressions, lymphomas, malignant processes, especially lymphoproliferation, metabolic syndrome. Patients with psoriasis, particularly if disease is severe, are at increased risk of cardiovascular diseases, such as hypertension, myocardial infarction, and stroke. Have examined the association between psoriasis and glomerulonephritis as well as chronic kidney disease. Factors influencing the course of psoriasis include age, stress, smoking, alcohol, a violation of diet, the presence of chronic obstructive pulmonary disease, sleep apnea, mental disorders The article presents an overview associations between psoriasis and metabolic syndrome. When a subject has three of the five listed criteria, a diagnosis of the metabolic syndrome can be made. The criteria listed include glucose intolerance presenting higher fasting glucose 6,1; increased waist circumference or abdominal obesity (≥ 102 cm for men and ≥ 88 cm for women); raised triglyceride levels ≥ 1.7 mmol/l; reduced high-density lipoprotein < 1.04 mmol/l for men and < 1.30 mmo/l for women; and elevated blood pressure 130/85 mmHg. In patients with psoriasis found a significantly increased prevalence and severity of coronary artery calcification.

About the authors

Albina G. Pashinyan

N.I. Pirogov Russian National Research Medical University

Email: stsoagp4@gmail.com
MD, PhD, DSc, prof. of N.I. Pirogov Russian National Research Medical University, Moscow, 117997, Russian Federation Moscow, 117997, Russian Federation

E. V Dontsova

Voronezh State Medical University n.a. N.N. Burdenko

394000, Voronezh, Russian Federation

References

  1. Верткин А.Л., Скотников А.С. Коморбидность. Лечащий врач. 2013; 6: 27-9
  2. Naldi L. Epidemiology of comorbidities in psoriasis. Dermatol. Ther. 2010; 23(2): 114-8. doi: 10.1111/j.1529-8019.2010.01304.
  3. Gerdes S., Mrowietz U., Boehncke W.H. Comorbidity in psoriasis. Hautarzt. 2016;67(6):438-44. doi: 10.1007/s00105-016-3805-3.
  4. Machado-Pinto J., Santos Diniz M., Couto Bavoso N. Psoriasis: new comorbidities. An Bras. Dermatol. 2016; 91(1): 8-14. doi: 10.1590/abd1806-4841.20164169
  5. Кактурский Л.В., Белова Е.В., Полосова Т.А., Михалева Я.М. Поражение сердца при псориазе. Архив патологии. 2004; 6: 22-3
  6. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 2007; 156(2): 271-6.
  7. Binus A.M., Han J., Qamar A.A., Mody E.A., Holt E.W., Qureshi A.A. Associated comorbidities in psoriasis and inflammatory bowel disease. J. Eur. Acad. Dermatol. Venereol. 2012; 26(5): 644-50. doi: 10.1111/j.1468-3083.2011.04153.
  8. Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol. Clin. 2015; 33(1): 41-55. doi: 10.1016/j.det.2014.09.004.
  9. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., Troxel A.B. The risk of stroke in patients with psoriasis. J. Invest. Dermatol. 2009; 129(10): 2411-8. doi: 10.1038/jid.2009.112.
  10. Cheng J., Kuai D., Zhang L., Yang X., Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch. Dermatol. Res. 2012; 304(2): 119-25. doi: 10.1007/s00403-011-1200-6.
  11. Egeberg A., Khalid U., Gislason G.H., Mallbris L., Skov L., Hansen P.R. Impact of Depression on Risk of Myocardial Infarction, Stroke and Cardiovascular Death in Patients with Psoriasis: A Danish Nationwide Study. Acta Derm. Venereol. 2016; 96(2): 218-21. doi: 10.2340/00015555-2218
  12. Davidovici B.B., Sattar N., Prinz J., Puig L., Emery P., Barker J.N., et al. Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J. Invest. Dermatol. 2010; 130(7): 1785-96. doi: 10.1038/jid.2010.103.
  13. Yang Y.W., Kang J.H., Lin H.C. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. Sleep Med. 2012; 13(3): 285-9. doi: 10.1016/j.sleep.2011.07.018.
  14. Chiu H.Y., Huang H.L., Li C.H., Yin Y.J., Chen H.A., Hsu S.T., et al. Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br. J. Dermatol. 2015; 173(1): 146-54. doi: 10.1111/bjd.13599.
  15. Basavaraj K.H., Navya M.A., Rashmi R. Stress and quality of life in psoriasis: an update. Int. J. Dermatol. 2011; 50(7): 783-92. doi: 10.1111/j.1365-4632.2010.04844.
  16. Пашинян А.Г., Донцова Е.В. Особенности липидного обмена у больных псориазом на фоне сопутствующего метаболического синдрома. Вестник дерматологии и венерологии. 2014; 4: 40-5
  17. Ma C., Harskamp C.T., Armstrong E.J., Armstrong A.W. The association between psoriasis and dyslipidaemia: a systematic review. Br. J. Dermatol. 2013; 168(3): 486-95. doi: 10.1111/bjd.12101
  18. Олисова О.Ю., Гаранян Л.Г. Коморбидности при псориазе. Российский журнал кожных и венерических болезней. 2016; 19(6): 346-8
  19. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J. Am. Acad. Dermatol. 2013; 68(4): 654-62 doi: 10.1016/j.jaad.2012.08.015.
  20. Salihbegovic E.M., Hadzigrahic N., Cickusic A.J. Psoriasis and metabolic syndrome. Med. Arch. 2015; 69(2): 85-7. doi: 10.5455/medarh.2015.69.85-87.
  21. Takahashi H., Iizuka H. Psoriasis and metabolic syndrome. J. Dermatol. 2012; 39(3): 212-8. doi: 10.1111/j.1346-8138.2011.01408.
  22. Love T.J., Qureshi A.A., Karlson E.W., Gelfand J.M., Choi H.K. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch. Dermatol. 2011; 147(4): 419-24. doi: 10.1001/archdermatol.2010.370.
  23. Дедов И.И., Мельниченко Г.А., ред. Эндокринология: национальное руководство. М.: ГЭОТАР-Медиа; 2008
  24. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new world-wide definition. Lancer. 2005; 366(9492): 1059-62.
  25. Hotamisligil G.S. Inflammation and metabolic disorders. Nature. 2006; 444(7121): 860-7.
  26. Мамедов М.Н. Консенсус Международной федерации диабета по определению метаболического синдрома: факты и комментарии. Рациональная фармакотерапия в кардиологии. 2009; 6: 47-50.
  27. Чубенко Е.А., Баранова Е.И., Шляхто Е.В. Ожирение и метаболический синдром. Роль гиперлептинемии в развитии абдоминального ожирения, инсулинорезистентности и артериальной гипертензии. Подходы к терапии. Lambert Academic Publishing; 2011.
  28. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298(7): 321-8.
  29. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-421.
  30. Перламутров Ю.Н., Микрюков А.В. Клинико-лабораторные характеристики псориаза, ассоциированного с гормональнометаболическими нарушениями. Российский журнал кожных и венерических болезней. 2013; 13(5): 46-50
  31. Uyanik B.S., Ari Z., Onur E., Gunduz K., Tanulku S., Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin. Chem. Lab. Med. 2002; 40(1): 65-8.
  32. Saleem M.D., Kesty C., Feldman S.R. Relative versus absolute risk of comorbidities in patients with psoriasis. J. Am. Acad. Dermatol. 2017; 76(3): 531-7. doi: 10.1016/j.jaad.2016.11.037.
  33. Khalid U., Hansen P.R., Gislason G.H., Lindhardsen J., Kristensen S.L., Winther S.A., et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013; 36(8): 2402-7. doi: 10.2337/dc12-2330.
  34. Lee M.S., Lin R.Y., Chang Y.T., Lai M.S. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int. J. Dermatol. 2012; 51(12): 1454-60. doi: 10.1111/j.1365-4632.2011.05310.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies